Targeting Alpha-Synuclein: Breakthroughs in the Quest to Halt Parkinson's Progression

5 (275) · $ 21.00 · In stock

The Odyssey of Alpha-synuclein and Neuroinflammatory Mediators as Potential Candidates in the Aetiology of Parkinson's Disease

Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets

Parkinson's vaccine effectively targets alpha-synuclein in Phase 1 trial, UB-312 reported to engage protein clumps, slow toxic buildup

Pathological Pathways and Alpha-Synuclein in Parkinson's Disease: A View from the Periphery

Study unveils mechanism regulating the transmission of a protein associated with the progression of Parkinson's disease

Vaxxinity Demonstrates Target Engagement of Toxic

Pharmaceutics, Free Full-Text

Neuronal haemoglobin induces loss of dopaminergic neurons in mouse Substantia nigra, cognitive deficits and cleavage of endogenous α-synuclein

Failure of the ubiquitin–proteasome system in Parkinson's disease

PDF) Targeting the Progression of Parkinson's Disease

New alpha-synuclein structures could be targeted by Parkinson's therapies

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease